Mario Lacouture

20PUBLICATIONS
83CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiologyImmunogenetics (incl. genetic immunology)Major global burdens of diseasePredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Jul 25, 2026
Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients.

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Dec 16, 2024
Phenotype/Immunologic Profiling in ircAEs-Response.

Elena Goleva, Mario E Lacouture, Andrea P Moy

|Oct 26, 2024
Management of human epidermal growth factor receptor inhibitors-related acneiform rash: A position paper based on the first Europe/USA Delphi consensus process.

Z Apalla, A Freites-Martinez, K Grafanaki

|Oct 09, 2024
Predictors of immediate and delayed cutaneous hypersensitivity reactions to paclitaxel.

Megan H Trager, Alyce M Kuo, Stephen W Dusza

|Apr 23, 2024
Immunologic Profiling of Immune-Related Cutaneous Adverse Events with Checkpoint Inhibitors Reveals Polarized Actionable Pathways.

Mario E Lacouture, Elena Goleva, Neil Shah

Pageof 4

Frequent Collaborators

4 joint publications

Lukas Kraehenbuehl

3 joint publications

Elena Goleva

3 joint publications

Andrea P Moy

3 joint publications

Donald Y M Leung